MedTrace Logo

A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

NCT07358156 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 519

Last updated 2026-01-23

No results posted yet for this study

Summary

This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.

Conditions

Interventions

DRUG

CKD-706

One subcutaneous dose of CKD-706 in pre-filled syringe, 300 mg/2mL

DRUG

US-Dupixent

One subcutaneous dose of US-Dupixent in pre-filled syringe, 300 mg/2mL

DRUG

EU-Dupixent

One subcutaneous dose of EU-Dupixent in pre-filled syringe, 300 mg/2mL

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-09
Primary Completion
2026-11-16
Completion
2026-11-16
FDA Drug
Yes

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07358156 on ClinicalTrials.gov